Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil

Germline mutations in BRCA1, BRCA2 and TP53 genes have been identified as one of the most important disease-causing issues in young breast cancer patients worldwide. The specific defective biological processes that trigger germline mutation-associated and -negative tumors remain unclear. To delineate an initial portrait of Brazilian early-onset breast cancer, we performed an investigation combining both germline and tumor analysis. Germline screening of the BRCA1, BRCA2, CHEK2 (c.1100delC) and TP53 genes was performed in 54 unrelated patients <35 y; their tumors were investigated with respect to transcriptional and genomic profiles as well as hormonal receptors and HER2 expression/amplification. Germline mutations were detected in 12 out of 54 patients (22%) [7 in BRCA1 (13%), 4 in BRCA2 (7%) and one in TP53 (2%) gene]. A cancer familial history was present in 31.4% of the unrelated patients, from them 43.7% were carriers for germline mutation (37.5% in BRCA1 and in 6.2% in the BRCA2 genes). Fifty percent of the unrelated patients with hormone receptor-negative tumors carried BRCA1 mutations, percentage increasing to 83% in cases with familial history of cancer. Over-representation of DNA damage-, cellular and cell cycle-related processes was detected in the up-regulated genes of BRCA1/2-associated tumors, whereas cell and embryo development-related processes were over-represented in the up-regulated genes of BRCA1/2-negative tumors, suggesting distinct mechanisms driving the tumorigenesis. An initial portrait of the early-onset breast cancer patients in Brazil was generated pointing out that hormone receptor-negative tumors and positive familial history are two major risk factors for detection of a BRCA1 germline mutation. Additionally, the data revealed molecular factors that potentially trigger the tumor development in young patients.

[1]  S. Seal,et al.  BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years , 2012, British Journal of Cancer.

[2]  P. Pearson,et al.  Germline DNA copy number variation in familial and early-onset breast cancer , 2012, Breast Cancer Research.

[3]  C. Sotiriou,et al.  Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling , 2012, Clinical Cancer Research.

[4]  Yixin Zeng,et al.  Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: a retrospective matched case-control study. , 2011, Breast.

[5]  Diane D. Liu,et al.  Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations , 2011, Breast Cancer Research and Treatment.

[6]  C. Perou,et al.  The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases , 2011, Cancer.

[7]  P. Defilippi,et al.  Integrin signalling adaptors: not only figurants in the cancer story , 2010, Nature Reviews Cancer.

[8]  A. Luini,et al.  Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Sapino,et al.  p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation , 2010, Oncogene.

[10]  S. Koifman,et al.  Environmental Exposure and Breast Cancer Among Young Women in Rio De Janeiro, Brazil , 2010, Journal of toxicology and environmental health. Part A.

[11]  M. Southey,et al.  Molecular characterization of breast cancer in young Brazilian women. , 2010, Revista da Associacao Medica Brasileira.

[12]  F. Carvalho,et al.  Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. , 2010, Breast.

[13]  M. Olivier,et al.  Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect , 2010, Human mutation.

[14]  A. Luini,et al.  Breast-conserving surgery in 201 very young patients (<35 years). , 2010, Breast.

[15]  D. Toppmeyer,et al.  Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Z. Aziz,et al.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30 , 2009, Familial Cancer.

[17]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[18]  Stephanie A Cohen,et al.  The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.

[19]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Soares,et al.  Imunofenótipo e evolução de câncer de mama: comparação entre mulheres muito jovens e mulheres na pós-menopausa , 2009 .

[21]  H. Brentani,et al.  Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma , 2008, Breast Cancer Research.

[22]  J. Marks,et al.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Bignon,et al.  BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases , 2008, International Journal of Medical Sciences.

[24]  M. Caleffi,et al.  Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. , 2008, Cancer genetics and cytogenetics.

[25]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[26]  I. Andrulis,et al.  Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study , 2007, Breast Cancer Research and Treatment.

[27]  A. Monteiro,et al.  Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil , 2007, Breast Cancer Research and Treatment.

[28]  J. Klijn,et al.  Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. , 2007, European journal of cancer.

[29]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[30]  K. Kyriacou,et al.  Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early‐onset breast cancer in Cyprus , 2007, Clinical genetics.

[31]  M. Olivier,et al.  The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. , 2007, Cancer letters.

[32]  M. Seoud,et al.  Effects of young age at presentation on survival in breast cancer , 2006, BMC Cancer.

[33]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[34]  P. Tan,et al.  Breast carcinoma in women 35 years and younger: a pathological study , 2006, Pathology.

[35]  Andrew Shenton,et al.  BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. , 2006, European journal of cancer.

[36]  J. Houwing-Duistermaat,et al.  Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping , 2006, Clinical Cancer Research.

[37]  Helena Brentani,et al.  Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer , 2005, Clinical Cancer Research.

[38]  Tara L. Naylor,et al.  Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. , 2005, Cancer research.

[39]  D. Easton,et al.  Contribution of BRCA1 and BRCA2 germ‐line mutations to the incidence of breast cancer in young women: Results from a prospective population‐based study in France , 2005, Genes, chromosomes & cancer.

[40]  Kristine Broglio,et al.  Women age < or = 35 years with primary breast carcinoma: disease features at presentation. , 2005, Cancer.

[41]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[42]  Masahiko Hoshijima,et al.  Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[43]  A. Cavaliere,et al.  Breast cancer in young women: clinicopathological features and biological specificity. , 2003, Breast.

[44]  M. Ringnér,et al.  Molecular classification of familial non-BRCA1/BRCA2 breast cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Luini,et al.  Very young women (<35 years) with operable breast cancer: features of disease at presentation. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[48]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  H. Gobbi,et al.  [Immunophenotype and evolution of breast carcinomas: a comparison between very young and postmenopausal women]. , 2009, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.

[50]  W. Han,et al.  Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer , 2009, Breast Cancer Research and Treatment.

[51]  M. A. Moreira,et al.  BRCA1 mutations in Brazilian patients , 2004 .